KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Idexx Laboratories (IDXX) over the last 16 years, with Sep 2025 value amounting to $31.1 million.

  • Idexx Laboratories' Capital Expenditures rose 10.77% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.5 million, marking a year-over-year increase of 0.22%. This contributed to the annual value of $120.9 million for FY2024, which is 9.51% down from last year.
  • Idexx Laboratories' Capital Expenditures amounted to $31.1 million in Q3 2025, which was down 8.76% from $34.1 million recorded in Q2 2025.
  • Over the past 5 years, Idexx Laboratories' Capital Expenditures peaked at $49.2 million during Q4 2022, and registered a low of $20.2 million during Q1 2021.
  • In the last 3 years, Idexx Laboratories' Capital Expenditures had a median value of $31.1 million in 2025 and averaged $31.8 million.
  • Examining YoY changes over the last 5 years, Idexx Laboratories' Capital Expenditures showed a top increase of 134.34% in 2021 and a maximum decrease of 58.85% in 2021.
  • Over the past 5 years, Idexx Laboratories' Capital Expenditures (Quarterly) stood at $31.8 million in 2021, then soared by 54.87% to $49.2 million in 2022, then tumbled by 33.87% to $32.6 million in 2023, then declined by 10.14% to $29.3 million in 2024, then rose by 10.77% to $31.1 million in 2025.
  • Its last three reported values are $31.1 million in Q3 2025, $34.1 million for Q2 2025, and $30.0 million during Q1 2025.